中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(10): 1992-1999

The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories： A bidirectional Mendelian randomization study

DOI: 10.12449/JCH241011
  • 1.

    Graduate School，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China

  • 2.

    Department of Integrative Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Beijing Municipal High Rank Public Health Researcher Training Program (Discipline Leader-03-04);

Capital Health Research and Development Project (2020-2-2172)

More Information
  • Corresponding author: YU Hao， yuhaodtyy@126.com （ORCID： 0000-0002-2213-0725）
  • Received Date: 2024-06-04
  • Accepted Date: 2024-07-25
  • Published Date: 2024-10-25
    Abstract
  •   Objective  To investigate the genetic association between nonalcoholic fatty liver disease （NAFLD） and type 2 diabetes mellitus （T2DM） using bidirectional two-sample Mendelian randomization （MR）， as well as the causal relationship between NAFLD and T2DM across different body mass index （BMI） categories.  Methods  The data were derived from genome-wide association studies conducted in European populations， with a sample size of 32 941 cases for NAFLD， 312 646 cases for T2DM， and 681 275 cases for BMI. The univariate and multivariate MR methods were used to assess the bidirectional causal relationship between NAFLD and T2DM in the general population and across different BMI subtypes. The methods of inverse-variance weighting， MR-Egger regression， constrained maximum likelihood and model averaging， and weighted median were used to conduct the MR analysis， and MR-Pleiotropy Residual Sum and Outlier， radial MR， the MR-Egger intercept method， and the Cochrane Q test were used for sensitivity analysis.  Results  The univariate MR analysis revealed a bidirectional causal relationship between NAFLD and T2DM in the general population （forward analysis： odds ratio ［OR］=9.75， 95% confidence interval ［CI］： 2.57‍ ‍—‍ ‍37.00， P<0.001； reverse analysis： OR=1.01， 95%CI： 1.00‍ ‍—‍ ‍1.01， P<0.01）. After adjustment for BMI， the multivariate MR analysis showed that the causal relationship between NAFLD and T2DM remained significant in the general population （OR=33.12， 95%CI： 7.57‍ ‍—‍ ‍144.95， P<0.000 1）. The subgroup analysis showed a causal relationship between NAFLD and T2DM across all BMI subtypes （lean subgroup： OR=12.19， 95%CI： 3.35‍ ‍—‍ ‍44.40， P<0.001； overweight subgroup： OR=4.30， 95%CI： 1.69‍ ‍—‍ ‍10.92， P<0.01； obese subgroup： OR=1.67， 95%CI： 1.14‍ ‍—‍ ‍2.44， P<0.01）.  Conclusion  This study reveals the causal relationship between NAFLD and T2DM in the general population of NAFLD and across different BMI subtypes from a genetic perspective.

     

    • FullText(HTML)
  • loading
    • References(49)
  • [1]
    POWELL EE, WONG VWS, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
    [2]
    RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
    [3]
    LI L, LIU DW, YAN HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies[J]. Obes Rev, 2016, 17( 6): 510- 519. DOI: 10.1111/obr.12407.
    [4]
    NABI O, LAPIDUS N, BOURSIER J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes(NASH-CO Study)[J]. Hepatology, 2023, 78( 1): 272- 283. DOI: 10.1097/HEP.0000000000000329.
    [5]
    XU R, PAN J, ZHOU W, et al. Recent advances in lean NAFLD[J]. Biomed Pharmacother, 2022, 153: 113331. DOI: 10.1016/j.biopha.2022.113331.
    [6]
    TANG A, NG CH, PHANG PH, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD-A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2023, 21( 7): 1750- 1760. e 12. DOI: 10.1016/j.cgh.2022.06.029.
    [7]
    International Diabetes Federation. IDF Diabetes Atlas(10th ed)[M]. Brussels: International Diabetes Federation, 2022.
    [8]
    YOUNOSSI ZM, GOLABI P, PRICE JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes[J]. Clin Gastroenterol Hepatol, 2024. DOI: 10.1016/j.cgh.2024.03.006.[ Online ahead of print]
    [9]
    CAO LM, AN Y, LIU HY, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: A systematic review and meta-analysis[J]. BMC Med, 2024, 22( 1): 101. DOI: 10.1186/s12916-024-03315-0.
    [10]
    GAO YT, ZHAO TY, SONG SN, et al. Lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: A literature review and meta-analysis[J]. Diabetes Res Clin Pract, 2023, 200: 110699. DOI: 10.1016/j.diabres.2023.110699.
    [11]
    BYRNE CD, TARGHER G. NAFLD: A multisystem disease[J]. J Hepatol, 2015, 62( 1 suppl): S47- S64. DOI: 10.1016/j.jhep.2014.12.012.
    [12]
    SEKULA P, FABIOLA GRECO M, PATTARO C, et al. Mendelian randomization as an approach to assess causality using observational data[J]. J Am Soc Nephrol, 2016, 27( 11): 3253- 3265. DOI: 10.1681/ASN.2016010098.
    [13]
    FERENCE BA, HOLMES MV, SMITH GD. Using Mendelian randomization to improve the design of randomized trials[J]. Cold Spring Harb Perspect Med, 2021, 11( 7): a040980. DOI: 10.1101/cshperspect.a040980.
    [14]
    SKRIVANKOVA VW, RICHMOND RC, WOOLF BAR, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: The STROBE-MR statement[J]. JAMA, 2021, 326( 16): 1614- 1621. DOI: 10.1001/jama.2021.18236.
    [15]
    SUN ZW, PAN XC, TIAN AW, et al. Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals[J]. JHEP Rep, 2023, 5( 7): 100744. DOI: 10.1016/j.jhepr.2023.100744.
    [16]
    O’CONNOR MJ, SCHROEDER P, HUERTA-CHAGOYA A, et al. Recessive genome-wide meta-analysis illuminates genetic architecture of type 2 diabetes[J]. Diabetes, 2022, 71( 3): 554- 565. DOI: 10.2337/db21-0545.
    [17]
    YENGO L, SIDORENKO J, KEMPER KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in ∼700000 individuals of European ancestry[J]. Hum Mol Genet, 2018, 27( 20): 3641- 3649. DOI: 10.1093/hmg/ddy271.
    [18]
    HEMANI G, TILLING K, DAVEY SMITH G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data[J]. PLoS Genet, 2017, 13( 11): e1007081. DOI: 10.1371/journal.pgen.1007081.
    [19]
    BURGESS S, SCOTT RA, TIMPSON NJ, et al. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors[J]. Eur J Epidemiol, 2015, 30( 7): 543- 552. DOI: 10.1007/s10654-015-0011-z.
    [20]
    BOWDEN J, DAVEY SMITH G, BURGESS S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44( 2): 512- 525. DOI: 10.1093/ije/dyv080.
    [21]
    XUE HR, SHEN XT, PAN W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects[J]. Am J Hum Genet, 2021, 108( 7): 1251- 1269. DOI: 10.1016/j.ajhg.2021.05.014.
    [22]
    BOWDEN J, DAVEY SMITH G, HAYCOCK PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted Median estimator[J]. Genet Epidemiol, 2016, 40( 4): 304- 314. DOI: 10.1002/gepi.21965.
    [23]
    SANDERSON E, DAVEY SMITH G, WINDMEIJER F, et al. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings[J]. Int J Epidemiol, 2019, 48( 3): 713- 727. DOI: 10.1093/ije/dyy262.
    [24]
    BURGESS S, THOMPSON SG. Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32( 5): 377- 389. DOI: 10.1007/s10654-017-0255-x.
    [25]
    VERBANCK M, CHEN CY, NEALE B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet, 2018, 50( 5): 693- 698. DOI: 10.1038/s41588-018-0099-7.
    [26]
    BOWDEN J, SPILLER W, DEL GRECO M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression[J]. Int J Epidemiol, 2018, 47( 6): 2100. DOI: 10.1093/ije/dyy265.
    [27]
    BOWDEN J, DEL GRECO M F, MINELLI C, et al. Improving the accuracy of two-sample summary-data Mendelian randomization: Moving beyond the NOME assumption[J]. Int J Epidemiol, 2019, 48( 3): 728- 742. DOI: 10.1093/ije/dyy258.
    [28]
    BURGESS S, BOWDEN J, FALL T, et al. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants[J]. Epidemiology, 2017, 28( 1): 30- 42. DOI: 10.1097/EDE.0000000000000559.
    [29]
    Fatty Liver and Alcoholic Liver Disease Group, Hepatology Branch of Chinese Medical Association. Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases[J]. J Clin Hepatol, 2010, 2( 4): 43- 48. DOI: 10.3969/j.issn.1674-7380.2010.04.013.

    中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26( 2): 120- 124. DOI: 10.3760/cma.j.jssn.1674-5809.2010.01.000.
    [30]
    LIU ZP, ZHANG Y, GRAHAM S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping[J]. J Hepatol, 2020, 73( 2): 263- 276. DOI: 10.1016/j.jhep.2020.03.006.
    [31]
    NI XT, TONG C, HALENGBIEKE A, et al. Association between nonalcoholic fatty liver disease and type 2 diabetes: A bidirectional two-sample Mendelian randomization study[J]. Diabetes Res Clin Pract, 2023, 206: 110993. DOI: 10.1016/j.diabres.2023.110993.
    [32]
    MANTOVANI A, BYRNE CD, BONORA E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis[J]. Diabetes Care, 2018, 41( 2): 372- 382. DOI: 10.2337/dc17-1902.
    [33]
    MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals[J]. Gut, 2021, 70( 5): 962- 969. DOI: 10.1136/gutjnl-2020-322572.
    [34]
    KOSMALSKI M, ŚLIWIŃSKA A, DRZEWOSKI J. Non-alcoholic fatty liver disease or type 2 diabetes mellitus-the chicken or the egg dilemma[J]. Biomedicines, 2023, 11( 4): 1097. DOI: 10.3390/biomedicines11041097.
    [35]
    KHAN RS, BRIL F, CUSI K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease[J]. Hepatology, 2019, 70( 2): 711- 724. DOI: 10.1002/hep.30429.
    [36]
    ZHANG XY, LIU Y, WANG WL, et al. Diagnosis and evaluation of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 8): 1780- 1788. DOI: 10.3969/j.issn.1001-5256.2023.08.003.

    张馨元, 刘宇, 王文玲, 等. 非酒精性脂肪性肝病的诊断与评估[J]. 临床肝胆病杂志, 2023, 39( 8): 1780- 1788. DOI: 10.3969/j.issn.1001-5256.2023.08.003.
    [37]
    ESLAM M, VALENTI L, ROMEO S. Genetics and epigenetics of NAFLD and NASH: Clinical impact[J]. J Hepatol, 2018, 68( 2): 268- 279. DOI: 10.1016/j.jhep.2017.09.003.
    [38]
    LIU DJ, PELOSO GM, YU HJ, et al. Exome-wide association study of plasma lipids in>300, 000 individuals[J]. Nat Genet, 2017, 49( 12): 1758- 1766. DOI: 10.1038/ng.3977.
    [39]
    BESSONE F, RAZORI MV, ROMA MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J]. Cell Mol Life Sci, 2019, 76( 1): 99- 128. DOI: 10.1007/s00018-018-2947-0.
    [40]
    MALONE JI, HANSEN BC. Does obesity cause type 2 diabetes mellitus(T2DM)? Or is it the opposite?[J]. Pediatr Diabetes, 2019, 20( 1): 5- 9. DOI: 10.1111/pedi.12787.
    [41]
    YE Q, ZOU BY, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5( 8): 739- 752. DOI: 10.1016/S2468-1253(20)30077-7.
    [42]
    PINGITORE P, ROMEO S. The role of PNPLA3 in health and disease[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864( 6): 900- 906. DOI: 10.1016/j.bbalip.2018.06.018.
    [43]
    ZHANG YJ, ZHOU XQ. Research advances in lean nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 12): 2914- 2919. DOI: 10.3969/j.issn.1001-5256.2023.12.024.

    张瑜娟, 周希乔. 瘦型非酒精性脂肪性肝病的研究进展[J]. 临床肝胆病杂志, 2023, 39( 12): 2914- 2919. DOI: 10.3969/j.issn.1001-5256.2023.12.024.
    [44]
    SMITH GI, POLIDORI DC, YOSHINO M, et al. Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics[J]. J Clin Invest, 2020, 130( 6): 3305- 3314. DOI: 10.1172/JCI136756.
    [45]
    TOBARI M, HASHIMOTO E, TANIAI M, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign[J]. J Gastroenterol Hepatol, 2019, 34( 8): 1404- 1410. DOI: 10.1111/jgh.14585.
    [46]
    PETTA S, CIMINNISI S, DI MARCO V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45( 4): 510- 518. DOI: 10.1111/apt.13889.
    [47]
    ZHOU XM, YU XY, SONG ZY. Clinical characteristics and management of lean nonalcoholic fatty liver disease[J]. Chin J Health Manag, 2024, 18( 3): 236- 240. DOI: 10.3760/cma.j.cn115624-20230803-00047.

    周馨媚, 余馨妍, 宋震亚. 瘦型非酒精性脂肪性肝病的临床特点和管理[J]. 中华健康管理学杂志, 2024, 18( 3): 236- 240. DOI: 10.3760/cma.j.cn115624-20230803-00047.
    [48]
    LI N, XANG W, WU SL, et al. Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: A retrospective cohort study with a 2-year follow-up period[J]. Front Endocrinol, 2023, 14: 1173757. DOI: 10.3389/fendo.2023.1173757.
    [49]
    FRACANZANI AL, PETTA S, LOMBARDI R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity[J]. Clin Gastroenterol Hepatol, 2017, 15( 10): 1604- 1611. e 1. DOI: 10.1016/j.cgh.2017.04.045.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (147) PDF downloads(22) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return